ITMCTR1900002376
Recruiting
Phase 1
Clinical study for the treatment of perimenopausal syndrome with the method of rank-side perforation
The Third Hospital of Shanxi College of Traditional Chinese Medicine ( Shanxi Provincial Acupuncture and Moxibustion Hospital)0 sitesTBD
ConditionsPerimenopausal syndrome
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Perimenopausal syndrome
- Sponsor
- The Third Hospital of Shanxi College of Traditional Chinese Medicine ( Shanxi Provincial Acupuncture and Moxibustion Hospital)
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •(1\) Comply with the diagnostic criteria for peri\-menopausal syndrome in Western medicine;
- •(2\) Comply with the diagnostic criteria for peri\-menopausal syndrome in Chinese medicine;
- •(3\) Baseline heating score \= 4 points;
- •(4\) Informed and agreed to participate in the study.
Exclusion Criteria
- •(1\) uterine and ovarian organic lesions; after ovarian, hysterectomy or local radiotherapy;
- •(2\) Those who have a pregnancy or are pregnant in the near future;
- •(3\) Currently receiving other therapies to treat the disease;
- •(4\) Patients with severe liver and kidney dysfunction, infectious diseases, cardiovascular and cerebrovascular diseases, and mental illness;
- •(5\) Those who have used sex hormones in the past 3 months.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 1
Clinical study on the treatment of Perimenopausal Insomnia with Yishen Pinggan DecoctioITMCTR2000003635Shanghai Municipal Hospital Traditional Chinese Medicine
Recruiting
Not Applicable
Clinical study on treatment of Postmenopausal Syndrome after operation of gynecologic malignant tumor with acupuncture and medicinePostmenopausal SyndromeITMCTR2100004484Zhejiang Provincial People's Hospital
Active, not recruiting
Not Applicable
First- Line Treatment of Postmenopausal Patients with Endocrine Responsive Metastatic Breast Cancer. A Randomized, Multicenter Study Comparing Letrozole Combined with Standard Chemotherapy Vs Letrozole Single Agent. The CELER (= CEsar LEtrozole Randomized phase III) Study - CELER Studyhormone-receptor-positive metastatic breast cancerMedDRA version: 8.0Level: PTClassification code 10055113EUCTR2005-001701-26-ATCESAR Central European Society for550
Active, not recruiting
Not Applicable
First- Line Treatment of Postmenopausal Patients with Endocrine Responsive Metastatic Breast Cancer. A Randomized, Multicenter Study Comparing Letrozole Combined with Standard Chemotherapy Vs Letrozole Single Agent. The CELER (= CEsar LEtrozole Randomized phase III) Study - CELER StudyEUCTR2005-001701-26-HUCESAR Central European Society for550
Active, not recruiting
Not Applicable
First- Line Treatment of Postmenopausal Patients with Endocrine Responsive Metastatic Breast Cancer. A Randomized, Multicenter Study Comparing Letrozole Combined with Standard Chemotherapy Vs Letrozole Single Agent. The CELER (= CEsar LEtrozole Randomized phase III) Study - CELER Studyhormone-receptor-positive metastatic breast cancerMedDRA version: 8.0Level: PTClassification code 10055113EUCTR2005-001701-26-SICESAR Central European Society for550